GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM, with at least 100 to 1000-fold functional selectivity in cells with PPARγ versus PPARα and PPARδ.
Acta Pharmacol Sin. 2020 Mar;41(3):373-382.
J Cell Mol Med. 2020 Jun;24(12):6833-6845.
Seizure-induced impairment in neuronal ketogenesis: Role of zinc-α2-glycoprotein in mitochondria
GW9662 purchased from AbMole
Life Sci. 2019 Dec 1;238:116979.
Effects of progesterone on glucose uptake in neurons of Alzheimer's disease animals and cell models.
GW9662 purchased from AbMole
|Source||J Cell Mol Med (2020 Jun). Figure 2. Pioglitazone (Abmole Bioscience, Houston, TX, USA)|
|Incubation Time||24 hours|
|Results||Compared to the DMSO group, a 24-hour treatment with pioglitazone increased the levels of the ZAG protein (1.013 ± 0.135 vs 0.654 ± 0.090, P = 0.004, n = 4) and AZGP1 mRNA (1.474 ± 0.078 vs 1, P = 0.003, n = 3) (Figure 2B,C), while GW9662 significantly decreased the levels of the ZAG protein (0.361 ± 0.097 vs 0.654 ± 0.090, P = 0.013, n = 4) and AZGP1 mRNA (0.482 ± 0.153 vs 1, P = 0.002, n = 3) (Figure 2B,C).|
|Source||Oncol Lett (2018). Figure 5. GW9662|
|Cell Lines||EC109 cells|
|Incubation Time||72 h|
|Results||GW9662 treatment attenuated the inhibitory effects of carotenoids on EC109 cell viability and the increase in PPARγ protein levels induced by carotenoids was reduced with GW9662 pre.treatment in EC109 cells.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 40 mg/mL|
The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion.
Collino M, et al. Kidney Int. 2005 Aug;68(2):529-36. PMID: 16014029.
GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
Seargent JM, et al. Br J Pharmacol. 2004 Dec;143(8):933-7. PMID: 15533890.
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.
Leesnitzer LM, et al. Biochemistry. 2002 May 28;41(21):6640-50. PMID: 12022867.
|Related PPAR Products|
LY518674 is a potent and selective PPAR-alpha antagonist with EC50 of 42 nM for human PPARα.
Pemafibrate is a potent and highly specific PPARα agonist, with EC50s of 1 nM, 1.10 μM and 1.58 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
Seladelpar (MBX-8025; RWJ-800025) is a selective peroxisome proliferator-activated receptor (SPPAR) -δ receptor agonist.
EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist.
Lanifibranor (IVA-337) is a peroxisome proliferator-activated receptors (PPAR) agonist, with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.